• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

儿童及旅行者中的耐药疟疾

Drug-resistant malaria in children and in travelers.

作者信息

Longworth D L

机构信息

Department of Infectious Diseases, Cleveland Clinic Foundation, Ohio, USA.

出版信息

Pediatr Clin North Am. 1995 Jun;42(3):649-64. doi: 10.1016/s0031-3955(16)38983-0.

DOI:10.1016/s0031-3955(16)38983-0
PMID:7761145
Abstract

Malaria remains a significant cause of childhood morbidity and mortality worldwide. Drug resistance in Plasmodium falciparum has become widespread in the past 30 years, and in some parts of the world multidrug resistance is common. Chloroquine resistance in Plasmodium vivax has recently been recognized in Indonesia. The mechanisms of drug resistance have been defined for the antifolate antimalarial agents but remain incompletely understood for the quinolines. Judicious use of antimalarial compounds will be essential to prevent the emergence and spread of further drug resistance. The history, geographic distribution, and mechanisms of drug resistance are reviewed, together with current recommendations regarding prophylaxis and therapy.

摘要

疟疾仍是全球儿童发病和死亡的一个重要原因。在过去30年里,恶性疟原虫的耐药性已广泛传播,在世界一些地区,多重耐药现象很常见。间日疟原虫对氯喹的耐药性最近在印度尼西亚被发现。抗叶酸抗疟药的耐药机制已明确,但喹啉类药物的耐药机制仍未完全了解。明智地使用抗疟化合物对于预防进一步的耐药性出现和传播至关重要。本文综述了耐药性的历史、地理分布和机制,以及目前关于预防和治疗的建议。

相似文献

1
Drug-resistant malaria in children and in travelers.儿童及旅行者中的耐药疟疾
Pediatr Clin North Am. 1995 Jun;42(3):649-64. doi: 10.1016/s0031-3955(16)38983-0.
2
Chloroquine resistant malaria in children.儿童氯喹耐药性疟疾
J Pak Med Assoc. 1998 Apr;48(4):98-100.
3
Chemoresistance of Plasmodium falciparum and Plasmodium vivax parasites in Brazil: consequences on disease morbidity and control.巴西疟原虫和间日疟原虫寄生虫的抗药性:对疾病发病率和控制的影响。
Mem Inst Oswaldo Cruz. 2011 Aug;106 Suppl 1:159-66. doi: 10.1590/s0074-02762011000900020.
4
[Plasmodium resistance to antimalarials].[疟原虫对抗疟药的耐药性]
Rev Prat. 2014 Dec;64(10):1433-4.
5
Susceptibility of Plasmodium falciparum to artemisinins and Plasmodium vivax to chloroquine in Phuoc Chien Commune, Ninh Thuan Province, south-central Vietnam.越南中南部宁顺省福川乡恶性疟原虫对青蒿素类药物的敏感性和间日疟原虫对氯喹的敏感性。
Malar J. 2019 Jan 17;18(1):10. doi: 10.1186/s12936-019-2640-2.
6
In vivo responses to antimalarials by Plasmodium falciparum and Plasmodium vivax from isolated Gag Island off northwest Irian Jaya, Indonesia.来自印度尼西亚伊里安查亚省西北部偏远的加格岛的恶性疟原虫和间日疟原虫对抗疟药的体内反应。
Am J Trop Med Hyg. 1999 Apr;60(4):542-6. doi: 10.4269/ajtmh.1999.60.542.
7
[Does the brief treatment with antimalarials favorably influence drug resistance and recurrences?].抗疟药的短期治疗是否对耐药性和复发有积极影响?
Rev Panam Salud Publica. 2001 Mar;9(3):202-4. doi: 10.1590/s1020-49892001000300015.
8
Plasmodium falciparum and Plasmodium vivax Demonstrate Contrasting Chloroquine Resistance Reversal Phenotypes.恶性疟原虫和间日疟原虫表现出相反的氯喹抗性逆转表型。
Antimicrob Agents Chemother. 2017 Jul 25;61(8). doi: 10.1128/AAC.00355-17. Print 2017 Aug.
9
Low efficacy of amodiaquine or chloroquine plus sulfadoxine-pyrimethamine against Plasmodium falciparum and P. vivax malaria in Papua New Guinea.在巴布亚新几内亚,阿莫地喹或氯喹联合磺胺多辛-乙胺嘧啶治疗恶性疟原虫和间日疟原虫疟疾的疗效较低。
Am J Trop Med Hyg. 2007 Nov;77(5):947-54.
10
The drug sensitivity and transmission dynamics of human malaria on Nias Island, North Sumatra, Indonesia.印度尼西亚北苏门答腊尼亚斯岛人类疟疾的药物敏感性及传播动态
Ann Trop Med Parasitol. 2002 Jul;96(5):447-62. doi: 10.1179/000349802125001249.

引用本文的文献

1
Therapy and drug resistance in malaria.疟疾的治疗与耐药性
Indian J Pediatr. 2000 Jan;67(1):33-5. doi: 10.1007/BF02802634.
2
Evaluation of the OptiMAL test for rapid diagnosis of Plasmodium vivax and Plasmodium falciparum malaria.评估OptiMAL检测法用于间日疟原虫和恶性疟原虫疟疾快速诊断的效果。
J Clin Microbiol. 1998 Jan;36(1):203-6. doi: 10.1128/JCM.36.1.203-206.1998.